• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Brazil Pharmaceuticals and Healthcare Report Q1 2009 - Product Image

Brazil Pharmaceuticals and Healthcare Report Q1 2009

  • Published: February 2009
  • Region: Brazil
  • 102 Pages
  • Business Monitor International


  • Aché / Biosintética
  • Eurofarma
  • Medley
  • Merck KGaA
  • Novo Nordisk
  • Pfizer
  • MORE

Brazil Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Brazil's pharmaceuticals and healthcare industry.

In the 10 months to October 2008, pharmaceutical sales in Brazil cam in at BRL25.0bn (US$12.4bn) before tax. Extrapolating this figure to the full year leads BMI to estimate that Brazil’s pharmaceutical market will grow at 6.8% in local currency terms in 2008, to reach a figure of BRL30.0 (US$14.9bn) for the full year. This represents a slight slowdown in comparison with previous years, due to the global economic slowdown.

Over the forecast period (2009-2013) BMI forecasts average growth of 6.2% for the pharmaceutical sector, with expenditure reaching BRL40.6bn (US$24.6bn) in 2013. Growth should continue to be driven by expanded access to healthcare, which can be expected to lead to significant increases in volume drug consumption; although this has not transpired in recent years due to the elimination of non-bioequivalent drugs. While the growing generics market and the government’s tough stance on patented drug prices should continue to hold down value growth, moves towards more stringent bioequivalence READ MORE >

Executive Summary
Brazil Pharmaceuticals And Healthcare Industry SWOT
Brazil Political SWOT
Brazil Economic SWOT
Brazil Business Environment SWOT

Pharmaceutical Business Environment Ratings
Table: Americas Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns

Brazil - Market Summary

Regulatory Regime
Intellectual Property
Regulator Interference
Data Protection
Compulsory Licensing
Intellectual Property Environment
Pricing And Reimbursement Issues
Other Regulatory Issues
Tax Burden On Pharmaceuticals

Industry Developments
Healthcare Sector
Domestic Pharmaceutical Industry
State-Owned Manufacturing Sector
PROFARMA Initiative
Generics Sector
Multinational Research-Based Sector
Research and Development
Distribution Sector
Retail Market

Industry Forecast Scenario
Overall Market Forecast
Table: Brazilian Drug Market Trends
Key Growth Factors - Industry
Table: Brazilian Health Expenditure Trends

Key Growth Factors - Macroeconomic
Table: Brazil - Economic Activity
Prescription Market Forecast
Table: Brazil’s Prescription Drug Market Trends (US$mn unless otherwise stated)
OTC Market Forecast
Regulatory Overview
OTC Sector: Competitive Landscape
Key Growth Factors
Table: Brazil’s OTC Market Trends (US$mn unless otherwise stated)
Generics Market Forecast
Competitive Landscape
Table: Brazil’s Generics And Patented Market Forecasts
Medical Device Market Forecast
Table: Brazil Medical Device Forecasts (US$mn unless otherwise stated)
Table: Pharmaceutical Trade Data And Forecasts (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Forecasts
Key Risks To BMI’s Forecast Scenario

Competitive Landscape
Leading Products

Company Monitor
Leading Multinational Companies
Merck & Co
GlaxoSmithKline (GSK)
Nycomed (Altana Pharma)
Merck KGaA
Novo Nordisk
Indigenous Manufacturing Sector
Aché / Biosintética
EMS Sigma

Country Snapshot: Brazil Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1999-2004
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 1996-2002

BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

- Sanofi-Aventis
- Pfizer
- Merck & Co
- Novartis
- GlaxoSmithKline (GSK)
- Roche
- Nycomed (Altana Pharma)
- Merck KGaA
- Novo Nordisk
- Aché / Biosintética
- EMS Sigma
- Eurofarma
- Medley

Note: Product cover images may vary from those shown



Our Clients

Our clients' logos